Inclusion Criteria:

          -  Histologically confirmed epithelial ovarian cancer, primary fallopian or primary
             peritoneal cancer.

          -  Platinum resistant epithelial ovarian cancer treated with at least two different
             previous chemotherapeutic regimens

          -  Progression on previous treatment. Previous treatment with bevacizumab is allowed.

          -  Measurable disease by the RECIST 1.1 criteria or evaluable by the GCIG CA-125
             criteria.

          -  Age ≥ 18 years.

          -  Performance status 0-2.

          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior
             to inclusion):

               -  WBC ≥ 3.0 x 10^9/l or neutrophils (ANC) ≥ 1.5 x 10^9/l

               -  Platelet count ≥ 100 x 10^9/l

               -  Hemoglobin ≥ 6 mmol/l

               -  Serum bilirubin < 2.0 x ULN

               -  Serum transaminase ≤ 2.5 x ULN

               -  Serum creatinine ≤ 1.5 ULN

          -  Urine dipstick for protein < 2+. If the dipstick shows protein ≥ 2+, 24 hour urine
             testing must be performed and show protein contents < 1 g.

          -  Written informed consent

        Exclusion Criteria:

          -  Other malignant disease within 3 years prior to inclusion in the study, except
             curatively treated basal cell or squamous cell carcinoma of the skin.

          -  Other experimental therapy or participation in another clinical trial within 28 days
             prior to treatment initiation.

          -  Intestinal infiltration or infiltration in major blood vessels at the discretion of
             the treating physician.

          -  Underlying medical disease not adequately treated (diabetes, cardiac disease).

          -  Uncontrolled hypertension (BP > 150/100 despite antihypertensive treatment).

          -  Surgery including open biopsy, within 4 weeks prior to first dose of bevacizumab.

          -  Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within
             6 months before start of treatment.

          -  Clinical significant cardiovascular disease, including:

               -  Myocardial infarction or unstable angina within 6 months before start of
                  treatment

               -  New York Heart Association (NYHA) class ≥ 2

               -  Poorly controlled cardiac arrhythmia despite medication

               -  Peripheral vascular disease grade ≥ 3

          -  Allergy to active substance or any of the auxiliary agents

          -  Bleeding tumor

          -  Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at
             screening is mandatory.

          -  Fertile patients not willing to use effective methods of contraception during
             treatment and for 6 months after the end of treatment.